This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

HistoRx Recognized As A 2010 Company To Watch By The Connecticut Technology Council

BRANFORD, Conn., Oct. 4 /PRNewswire/ -- HistoRx was recognized as a 2010 Company to Watch by the Connecticut Technology Council at the Innovation Pipeline Awards ceremony last week in New Haven, Connecticut.  HistoRx was recognized for significant milestones achieved in 2010:

  • launching its proprietary AQUA® technology software on a second hardware platform -- the ScanScope FL from Aperio
  • signing a licensing deal with a national oncology reference lab for AQUA technology and several diagnostic assays based on it -- Genoptix Medical Laboratory (Nasdaq: GXDX)
  • receiving a U.S. patent for an application of AQUA technology to personalized medicine -- methods for determining a cancer patient's prognosis based on sub-cellular localization of biomarkers, specifically thymidylate synthase (TS)

These achievements represent key indicators of the company's maturation from a life science technology company to a diagnostics developer nearing first clinical use of its products.

The Innovation & Entrepreneurship Summit is a juried event designed to showcase the products and services from approximately 100 exciting early stage companies in various advanced technology categories.  Each year the event draws several hundred investors, corporate business development executives, prospective customers and the media.  This multifaceted event included a technology showcase of the award-winning Companies to Watch, and focused on young, emerging technology companies with an innovative product or service and the potential to grow quickly.

The Connecticut Technology Council is a statewide association of technology oriented companies and institutions, providing leadership in areas of policy advocacy, community building and assistance for growing companies.  Speaking for over 2,000 companies that employ some 200,000 residents, the Connecticut Technology Council seeks to provide a strong and urgent voice in support of the creation of a culture of innovation.

HistoRx, Inc. is a leading developer of tissue-based theranostic solutions to advance individualized patient care.  The Company's products and services are based on proprietary AQUA® technology for tissue biomarker analysis.  AQUA® software is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decision making.  HistoRx currently helps biopharmaceutical companies advance their product pipelines by generating valuable new insights into the safety and effectiveness of targeted therapeutics in development for cancer and other diseases, and is developing clinical assays based on these insights.  The first clinical diagnostics based on AQUA® technology will be launched in late 2010.  For more information please visit:   www.historx.com.

SOURCE HistoRx, Inc.

Copyright 2009 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,814.11 +95.11 0.54%
S&P 500 2,064.89 +12.14 0.59%
NASDAQ 4,725.5190 +23.6520 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs